Skip to main content

$0.091 0.002 (2.25%)

High

$0.10

Low

$0.09

Trades

2,797

Turnover

$4,713,392

Volume

50,159,971
30 June 2023 at 4:59pm
Register to track IMU and receive email alerts.
Subject
IMU Ann: Change of Director's Interest Notice

IMU Ann: HER-Vaxx induced antibodies correlated with tumour reduction

IMU Ann: Imugene PD1-Vaxx patent extended to 2040

IMU Ann: Initial Director's Interest Notice

IMU Ann: Imugene Appoints Kim Drapkin as Non-Executive Director

IMU Ann: Imugene Advances VAXINIA MAST Trial to Next IV Cohorts

IMU Ann: Imugene doses first combination patient in PD1-Vaxx trial

IMU Ann: Imugene Investor Webinar - FDA IND Clearance for onCARlytics

IMU Ann: FDA clears Imugene IND for onCARlytics first-in-class study

IMU Ann: onCARlytics with ARTEMIS T cells show anti-tumour activity

IMU Ann: onCARlytics with Artemis T cells abstract presented at ASGCT

IMU Ann: Quarterly Activities/Appendix 4C Cash Flow Report

IMU Ann: Imugene receives $12.6m R&D tax refund

IMU Ann: Imugene Images and Follows CHECKVacc in TNBC Patients

IMU Ann: First patients dosed in IT & IV cohort 3 of VAXINIA trial

IMU Ann: Imugene Presentation to NWR Healthcare Conference

IMU Ann: Imugene to present at NWR Virtual Healthcare Conference

IMU Ann: Imugene Corporate Presentation

IMU Ann: Notice Under Section 708A

IMU Ann: Notification regarding unquoted securities - IMU

IMU Ann: Application for quotation of securities - IMU

IMU Ann: Change of Registered Office

IMU Ann: First Patients Dosed in Combination Study of VAXINIA

IMU Ann: Imugene appoints CFO Mike Tonroe as Company Secretary

IMU Ann: Half Yearly Report and Accounts

IMU Ann: Application for quotation of securities - IMU

IMU Ann: Imugene PD1-Vaxx Immunotherapy Patent Granted in the US

IMU Ann: Imugene VAXINIA trial advances to Combination Cohort

IMU Ann: Quarterly Activities/Appendix 4C Cash Flow Report

IMU Ann: HER-Vaxx and CF33 Platforms Featured at ASCO Symposium

IMU Ann: Imugene Presentation to the JP Morgan Healthcare Conference

IMU Ann: Imugene Receives Vaxinia Ethics Approval in Australia

IMU Ann: Letter to Shareholders

IMU Ann: Notification regarding unquoted securities - IMU

IMU Ann: Notification regarding unquoted securities - IMU

IMU Ann: Ceasing to be a substantial holder

IMU Ann: Ceasing to be a substantial holder

IMU Ann: Change of Director's Interest Notice x6

IMU Ann: Notification of cessation of securities - IMU

IMU Ann: Notification regarding unquoted securities - IMU

IMU Ann: Imugene HER-Vaxx and CF33 Platforms To Feature at ASCO

IMU Ann: Imugene to Present at J.P. Morgan Healthcare Conference

IMU Ann: CHECKVacc Data Presented at the 2022 SABC Symposium

IMU Ann: Appendix 3H

IMU Ann: Notice Under Section 708A

IMU Ann: Appendix 2A

IMU Ann: First Patient Dosed in VAXINIA Intravenous Cohort 2

IMU Ann: Positive New HER-Vaxx HERIZON Data Presented at ESMO Asia

IMU Ann: Application for quotation of securities - IMU

IMU Ann: Application for quotation of securities - IMU

Register to track IMU and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
MSB
OPT
PAR
PYC
RAC
TLX